Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 17/20 | 0.62 |
| ▸ | NTSR2 | O95665 | 15/20 | 0.62 |
| ▸ | SORT1 | Q99523 | 13/20 | 0.59 |
| ▸ | F2 | P00734 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860392 | 0.94 | NTSR1 (0.64) | NTSR1NTSR2SORT1SLC6A2 | |
| SCHEMBL30637760 | 0.94 | NTSR1 (0.64) | NTSR1NTSR2SORT1SLC6A2 | |
| SCHEMBL30921554 | 0.92 | SLC6A2 (0.67) | NTSR1NTSR2SORT1SLC6A2 | |
| SCHEMBL19220695 | 0.91 | NTSR1 (0.63) | NTSR1NTSR2SORT1 | |
| SCHEMBL29967012 | 0.90 | NTSR1 (0.68) | NTSR1NTSR2SORT1 | |
| SCHEMBL2039240 | 0.90 | NTSR1 (0.68) | NTSR1NTSR2SORT1 | |
| SCHEMBL28111222 | 0.88 | F2 (0.63) | NTSR1NTSR2SORT1F2 | |
| SCHEMBL29860120 | 0.88 | F2 (0.64) | NTSR1NTSR2SORT1F2 | |
| SCHEMBL30969929 | 0.87 | F2 (0.58) | NTSR1NTSR2SORT1F2 | |
| SCHEMBL24195742 | 0.86 | F2 (0.65) | NTSR1NTSR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10376532-B2 | Methods of treating, reducing the incidence of, and/or preventing ischemic events | CHIESI FARMACEUTICI, S.P.A. (IT) | 2019-08-13 | — | — | US | disclosed |
| US-9925265-B2 | Methods of treating or preventing stent thrombosis | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10376532-B2 | Methods of treating, reducing the incidence of, and/or preventing ischemic events | P2RY12, P2RY11, PTAFR | NTSR1 892/4885NTSR2 1068/4885SORT1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.